WIN 2017 conference review
5 Jul 2017
WIN 2017 conference review
The challenge of approving add-on therapies for patients with metastatic cancer
Molecular medicine in lung cancer
Current and future immune approaches in precision medicine
Precision medicine enabled histology agnostic development of immunotherapeutics
Incorporating liquid biopsies into clinical trials
Bayesian adaptive trial designs for precision medicine
Redesigning clinical trials in the era of precision medicine
Synthetic lethality as a basis to select drug combinations
Patient-specific peptide vaccines
Proteogenomics in cancer research
Novel models to personalise cancer therapeutics